BioControl Medical Ltd. has terminated the INOVATE HF
trial of its CardioFit vagus nerve stimulator (VNS) for the treatment of heart failure after a pre-specified interim analysis showed...
BioControl Becomes Latest Company To Report Disappointing Outcomes With VNS Therapy For Heart Failure
BioControl Medical has terminated the INOVATE HF trial of its CardioFit vagus nerve stimulator (VNS) for the treatment of heart failure after a pre-specified interim analysis showed the trial had little chance of meeting its primary endpoint. Despite the disappointing results, some physicians remain optimistic about VNS for heart failure and researchers continue to analyze patient subgroups and secondary endpoints to identify potential patients who might benefit from VNS therapy.
More from Clinical Trials
• By
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
• By
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
• By
SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.
• By
The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.
More from R&D
• By
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
• By
SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.
• By
Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.